Breaking News Instant updates and real-time market news.

NVS

Novartis

$83.48

-0.19 (-0.23%)

, APDN

Applied DNA Sciences

$1.23

0.04 (3.36%)

04:55
08/31/18
08/31
04:55
08/31/18
04:55

Cambridge Healthtech Institute to hold a summit

5th Annual Immuno-Oncology Summit to be held in Boston on August 27-31.

NVS

Novartis

$83.48

-0.19 (-0.23%)

APDN

Applied DNA Sciences

$1.23

0.04 (3.36%)

LMNX

Luminex

$28.01

-0.16 (-0.57%)

PKI

PerkinElmer

$92.64

2.59 (2.88%)

  • 06

    Sep

  • 12

    Sep

NVS Novartis
$83.48

-0.19 (-0.23%)

08/29/18
JPMS
08/29/18
UPGRADE
Target $75
JPMS
Overweight
JPMorgan upgrades Glaukos after 'main competitor' pulls product
As previously reported, JPMorgan analyst Robert Marcus upgraded Glaukos (GKOS) to Overweight from Neutral, calling Alcon's (NVS) voluntary withdrawal of its micro-stent from the market a "significant win" that opens up an opportunity for Glaukos to take back principally all of the sales being generated by CyPass. Stating that he's always been a firm believer in Glaukos' pipeline and technology, Marcus said competition had been the main factor keeping him on the sidelines. Now that its "main competitor" is out of the way, he sees Glaukos having a meaningful opportunity to recapture share and lead the market. Marcus raised his price target on the stock to $75 from $42.
08/30/18
BMOC
08/30/18
NO CHANGE
Target $59
BMOC
Market Perform
Glaukos price target raised to $59 from $44 at BMO Capital
BMO Capital analyst Joanne Wuensch raised her price target on Glaukos (GKOS) to $59 after the stock price spiked up 40% above $62 yesterday following Novartis' (NVS) Alcon unit withdrawal of the CyPass micro-stent from the market due to safety concerns. The analyst keeps her Market Perform rating however, saying her conversations with physicians suggest that the CyPass cessation does not appear to be a "class effect" and that it will likely return at some stage. Wuensch added that Glaukos's iStent may not necessarily capture all of Alcon's market share, stating that "different devices are right for different patients".
08/30/18
WELS
08/30/18
NO CHANGE
Target $74
WELS
Outperform
Glaukos price target raised to $74 from $50 at Wells Fargo
Wells Fargo analyst Larry Biegelsen raised his price target for Glaukos (GKOS) to $74 from $50, while reiterating an Outperform rating on the shares. The analyst notes that Novartis (NVS) stated it was removing its CyPass micro invasive glaucoma surgery device from the global market due to 5-year data, which showed statistically significant endothelial cell loss for CyPass compared to the group, who underwent cataract surgery alone. The analyst believes the issue is CyPass-specific and expects Glaukos to materially benefit from Alcon's exit beginning in Q4 and years ahead.
08/29/18
SPHN
08/29/18
NO CHANGE
Target $57
SPHN
Overweight
Glaukos price target raised to $57 at Stephens after Novartis withdraws CyPass
Stephens analyst Chris Cooley raised his price target on Glaukos (GKOS) shares to $57 from $50 after Novartis' (NVS) Alcon unit withdrew the CyPass micro-stent from the market due to safety concerns. He estimates $40M-$50M in annual sales are now "in play" and see Glaukos as the most likely beneficiary, Cooley tells investors. He maintains an Overweight rating on Glaukos shares, which are up $17.35, or 39%, to $62.15 in pre-market trading.
APDN Applied DNA Sciences
$1.23

0.04 (3.36%)

04/23/18
MAXM
04/23/18
INITIATION
Target $5
MAXM
Buy
Applied DNA Sciences assumed with a Buy at Maxim
Maxim analyst Anthony Vendetti assumed coverage of Applied DNA Sciences with a Buy rating and $5 price target. The rating and price target are unchanged from Maxim's prior coverage under analyst Brian Kinstlinger.
LMNX Luminex
$28.01

-0.16 (-0.57%)

05/07/18
DBAB
05/07/18
UPGRADE
Target $22
DBAB
Hold
Luminex upgraded to Hold from Sell at Deutsche Bank
Deutsche Bank analyst Dan Leonard upgraded Luminex to Hold and raised his price target for the shares to $22 from $19. The analyst views the risk/reward as balanced at current share levels.
PKI PerkinElmer
$92.64

2.59 (2.88%)

09/26/17
GSCO
09/26/17
INITIATION
Target $67
GSCO
Neutral
PerkinElmer assumed with a Neutral at Goldman Sachs
Goldman analyst Patrick Donnelly assumed coverage on PerkinElmer with a Neutral and $67 price target. The analyst expects below peer growth to continue and believes managements operating profit margin goal of 22% by 2020 is aggressive.
08/30/18
CLVD
08/30/18
UPGRADE
CLVD
Buy
PerkinElmer upgraded to Buy from Neutral at Cleveland Research
01/03/18
EVER
01/03/18
INITIATION
Target $77
EVER
In Line
PerkinElmer initiated with an In Line at Evercore ISI
Evercore ISI analyst Ross Muken initiated PerkinElmer with an In Line rating and $77 price target.
12/19/17
BOFA
12/19/17
UPGRADE
Target $78
BOFA
Neutral
PerkinElmer upgraded to Neutral from Underperform at BofA/Merrill
BofA/Merrill analyst Derik De Bruin upgraded PerkinElmer to Neutral and raised its price target to $78 from $70 ahead ot the pending $1.3B Eurolmmun acquisition. De Bruin said PerkinElmer has been pruning non-core and slower businesses and Eurolmmun is a key step in the portfolio transition with its solid and price competitive autoimmune testing business.

TODAY'S FREE FLY STORIES

03:05
12/10/18
12/10
03:05
12/10/18
03:05
General news
FX Update: The Dollar and Sterling have come under general pressure »

FX Update: The Dollar…

YELP

Yelp

$34.60

0.19 (0.55%)

20:47
12/09/18
12/09
20:47
12/09/18
20:47
Periodicals
Yelp holder SQN to send letter pushing for business review, WSJ reports »

SQN Investors, a 4%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

GILD

Gilead

$68.17

-2.01 (-2.86%)

, RHHBY

Roche

$0.00

(0.00%)

20:38
12/09/18
12/09
20:38
12/09/18
20:38
Periodicals
Gilead to hire Roche's Daniel O'Day as next CEO, WSJ reports »

Gilead Sciences (GILD)…

GILD

Gilead

$68.17

-2.01 (-2.86%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 24

    Dec

  • 18

    Mar

UN

Unilever; also tag UL

$55.49

0.13 (0.23%)

, UL

Unilever; also tag UN

$54.04

0.17 (0.32%)

20:29
12/09/18
12/09
20:29
12/09/18
20:29
Downgrade
Unilever; also tag UL, Unilever; also tag UN rating change at JPMorgan »

Unilever downgraded to…

UN

Unilever; also tag UL

$55.49

0.13 (0.23%)

UL

Unilever; also tag UN

$54.04

0.17 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

JELD

Jeld-Wen

$16.85

-0.61 (-3.49%)

20:27
12/09/18
12/09
20:27
12/09/18
20:27
Downgrade
Jeld-Wen rating change at Goldman Sachs »

Jeld-Wen downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBHS

Fortune Brands

$42.60

0.07 (0.16%)

20:27
12/09/18
12/09
20:27
12/09/18
20:27
Upgrade
Fortune Brands rating change at Goldman Sachs »

Fortune Brands upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANPDY

Anta Sports Products

$0.00

(0.00%)

19:46
12/09/18
12/09
19:46
12/09/18
19:46
Downgrade
Anta Sports Products rating change at Deutsche Bank »

Anta Sports Products…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KREF

KKR Real Estate Finance

$19.71

-0.095 (-0.48%)

19:42
12/09/18
12/09
19:42
12/09/18
19:42
Upgrade
KKR Real Estate Finance rating change at Keefe Bruyette »

KKR Real Estate upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KTOS

Kratos Defense

$13.64

-0.11 (-0.80%)

19:34
12/09/18
12/09
19:34
12/09/18
19:34
Upgrade
Kratos Defense rating change at Goldman Sachs »

Kratos Defense upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$168.37

-6.37 (-3.65%)

, MSFT

Microsoft

$104.90

-4.27 (-3.91%)

19:30
12/09/18
12/09
19:30
12/09/18
19:30
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

AAPL

Apple

$168.37

-6.37 (-3.65%)

MSFT

Microsoft

$104.90

-4.27 (-3.91%)

DIS

Disney

$112.00

-1.385 (-1.22%)

PYPL

PayPal

$82.78

-3.07 (-3.58%)

AMAT

Applied Materials

$33.65

-1.04 (-3.00%)

CAT

Caterpillar

$123.54

-4.69 (-3.66%)

LEN

Lennar

$42.00

-0.43 (-1.01%)

NFLX

Netflix

$265.14

-17.66 (-6.24%)

PANW

Palo Alto Networks

$175.11

-6.73 (-3.70%)

DB

Deutsche Bank

$8.74

-0.155 (-1.74%)

LITE

Lumentum

$41.92

-2.81 (-6.28%)

OCLR

Oclaro

$8.27

-0.165 (-1.96%)

FNSR

Finisar

$22.49

-0.53 (-2.30%)

ZTCOY

ZTE Corp.

$0.00

(0.00%)

CIEN

Ciena

$31.30

-0.95 (-2.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

  • 13

    Dec

  • 13

    Dec

  • 18

    Dec

  • 19

    Dec

  • 09

    Jan

  • 10

    Jan

  • 03

    Mar

LITE

Lumentum

$41.92

-2.81 (-6.28%)

, OCLR

Oclaro

$8.27

-0.165 (-1.96%)

18:16
12/09/18
12/09
18:16
12/09/18
18:16
Periodicals
Huawei CFO seeking bail, Reuters reports »

Huawei Chief Financial…

LITE

Lumentum

$41.92

-2.81 (-6.28%)

OCLR

Oclaro

$8.27

-0.165 (-1.96%)

FNSR

Finisar

$22.49

-0.53 (-2.30%)

ZTCOY

ZTE Corp.

$0.00

(0.00%)

INFN

Infinera

$4.38

-0.21 (-4.58%)

CIEN

Ciena

$31.30

-0.95 (-2.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

KERX

Keryx

$3.14

-0.035 (-1.10%)

, AKBA

Akebia

$8.52

-0.02 (-0.23%)

16:51
12/09/18
12/09
16:51
12/09/18
16:51
Conference/Events
Akebia to host special shareholder meeting »

Special Shareholder…

KERX

Keryx

$3.14

-0.035 (-1.10%)

AKBA

Akebia

$8.52

-0.02 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

AKBA

Akebia

$8.52

-0.02 (-0.23%)

, KERX

Keryx

$3.14

-0.035 (-1.10%)

16:49
12/09/18
12/09
16:49
12/09/18
16:49
Conference/Events
Keryx to host special shareholder meeting »

Special Shareholder…

AKBA

Akebia

$8.52

-0.02 (-0.23%)

KERX

Keryx

$3.14

-0.035 (-1.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

DVMT

Dell Technologies

$104.01

-1.51 (-1.43%)

16:35
12/09/18
12/09
16:35
12/09/18
16:35
Conference/Events
Dell Technologies to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 07

    Mar

T

AT&T

$30.14

-0.38 (-1.25%)

, CMCSA

Comcast

$37.41

-0.46 (-1.21%)

16:34
12/09/18
12/09
16:34
12/09/18
16:34
Hot Stocks
Box Office Battle: 'Ralph Breaks the Internet' leads top office with $16.1M »

Disney's (DIS)…

T

AT&T

$30.14

-0.38 (-1.25%)

CMCSA

Comcast

$37.41

-0.46 (-1.21%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$51.19

-0.67 (-1.29%)

FOX

21st Century Fox

$48.99

-0.23 (-0.47%)

FOXA

21st Century Fox

$49.26

-0.21 (-0.42%)

LGF.A

Lionsgate

$17.58

0.28 (1.62%)

DIS

Disney

$112.00

-1.385 (-1.22%)

VIAB

Viacom

$29.91

-0.09 (-0.30%)

VIA

Viacom

$33.19

0.11 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 30

    Jan

  • 20

    Mar

CNC

Centene

$133.28

-2.1 (-1.55%)

16:09
12/09/18
12/09
16:09
12/09/18
16:09
Conference/Events
Centene to hold a meeting »

2019 Financial Guidance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

FTI

TechnipFMC

$21.00

-0.69 (-3.18%)

16:00
12/09/18
12/09
16:00
12/09/18
16:00
Conference/Events
TechnipFMC to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPRX

Catalyst Pharmaceuticals

$2.39

0.16 (7.17%)

15:56
12/09/18
12/09
15:56
12/09/18
15:56
Conference/Events
Catalyst Pharmaceuticals to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

WPP

WPP

$52.11

-0.39 (-0.74%)

14:22
12/09/18
12/09
14:22
12/09/18
14:22
Conference/Events
WPP to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

VISI

Volt Information Sciences

$2.64

-0.05 (-1.86%)

14:11
12/09/18
12/09
14:11
12/09/18
14:11
Conference/Events
Volt Information Sciences to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

ARCT

Arcturus Therapeutics

$5.90

0.45 (8.26%)

13:52
12/09/18
12/09
13:52
12/09/18
13:52
Conference/Events
Arcturus Therapeutics to hold a conference call »

Key Opinion Leader…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

STWD

Starwood Property

$22.34

-0.08 (-0.36%)

13:37
12/09/18
12/09
13:37
12/09/18
13:37
Conference/Events
Starwood Property to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

EZPW

Ezcorp

$8.74

-0.17 (-1.91%)

13:31
12/09/18
12/09
13:31
12/09/18
13:31
Conference/Events
Ezcorp to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

NFLX

Netflix

$265.14

-17.66 (-6.24%)

, PANW

Palo Alto Networks

$175.11

-6.73 (-3.70%)

13:20
12/09/18
12/09
13:20
12/09/18
13:20
Periodicals
Netflix, Palo Alto offer growth at a discount, Barron's says »

As stocks search for a…

NFLX

Netflix

$265.14

-17.66 (-6.24%)

PANW

Palo Alto Networks

$175.11

-6.73 (-3.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 19

    Dec

  • 09

    Jan

  • 10

    Jan

DHR

Danaher

$101.94

-2.88 (-2.75%)

13:18
12/09/18
12/09
13:18
12/09/18
13:18
Conference/Events
Danaher to host analyst and investor meeting »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.